Does addition of sitagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus?

Nature Clinical Practice Endocrinology and Metabolism

Volumn 3, Issue 6, 2007, Pages 450-451

  Salsali, Afshin ^a   Pratley, Richard E ^a,b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; SITAGLIPTIN;

ADULT; AGED; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INCIDENCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; OUTCOMES RESEARCH; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; WEIGHT GAIN;

EID: 34249311960     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0512     Document Type: Note

References (5)

1. King H et al. (1998) Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21: 1414-1431
2. Drucker DJ and Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705
3. Deacon CF (2005) MK-431 (Merck). Curr Opin Investig Drugs 6: 419-426
4. Nathan DM et al. (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49: 1711-1721
5. Nauck MA et al. (2007) Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 9: 194-205